The need to modify patient selection to improve the benefits of implantable cardioverter-defibrillator for primary prevention of sudden death in non-ischaemic dilated cardiomyopathy

Europace

Volumn 15, Issue 12, 2013, Pages 1693-1701

  Disertori, Marcello ^a,b   Quintarelli, Silvia ^b   Mazzola, Silvia ^b   Favalli, Valentina ^c   Narula, Nupoor ^c,d   Arbustini, Eloisa ^c  

^a FONDAZIONE BRUNO KESSLER   (Italy)

^b SANTA CHIARA HOSPITAL   (Italy)

^c FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^d MAYO CLINIC   (United States)

Author keywords

Cardiac magnetic resonance; Cardioverter defibrillator; Dilated cardiomyopathy; Hereditability; Sudden death primary prevention; T wave alternans

Indexed keywords

AMIODARONE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; GADOLINIUM;

ALGORITHM; CARDIAC RESYNCHRONIZATION THERAPY; CARDIOVASCULAR MAGNETIC RESONANCE; CONGESTIVE CARDIOMYOPATHY; DISEASE CLASSIFICATION; ELECTROCARDIOGRAM; GENE; GENE MUTATION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART RATE TURBULENCE; HEART RATE VARIABILITY; HUMAN; IMAGE ENHANCEMENT; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; LAMIN A GENE; PATIENT SELECTION; PRACTICE GUIDELINE; PREDICTIVE VALUE; PRESSORECEPTOR REFLEX; PRIMARY PREVENTION; PRIORITY JOURNAL; QRS COMPLEX; QT DISPERSION; QT INTERVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SHOCK; SUDDEN DEATH; T WAVE; TREATMENT INDICATION;

CARDIAC MAGNETIC RESONANCE; CARDIOVERTER DEFIBRILLATOR; DILATED CARDIOMYOPATHY; HEREDITABILITY; SUDDEN DEATH PRIMARY PREVENTION; T-WAVE ALTERNANS;

ALGORITHMS; CARDIOMYOPATHY, DILATED; DEATH, SUDDEN, CARDIAC; DECISION SUPPORT TECHNIQUES; DEFIBRILLATORS, IMPLANTABLE; DNA MUTATIONAL ANALYSIS; ELECTRIC COUNTERSHOCK; ELECTROCARDIOGRAPHY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MAGNETIC RESONANCE IMAGING; PATIENT SELECTION; PRACTICE GUIDELINES AS TOPIC; PREDICTIVE VALUE OF TESTS; PRIMARY PREVENTION; RISK ASSESSMENT; RISK FACTORS; STROKE VOLUME; TREATMENT OUTCOME; VENTRICULAR FUNCTION, LEFT;

EID: 84890500594     PISSN: 10995129     EISSN: 15322092     Source Type: Journal    
DOI: 10.1093/europace/eut228     Document Type: Review

References (86)

1. Mirowski M, Reid PR,MowerMM,Watkins L, Gott VL, Schauble JF et al. Termination of malignant ventricular arrhythmias with an implantable automatic defibrillator in human beings. N Engl J Med 1980;303:322-44.
2. Moss A, ZarebaW, HallW, Klein H, Wilberg DJ, Cannom DS et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002;346:877-83.
3. Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.NEngl J Med 2005; 352:225-37.
4. Ezekowitz JA, Rowe BH, Dryden DM, Hooton N, Vandermeer B, Spooner C et al. Systematic review: implantable cardioverter defibrillators for adults with left ventricular systolic dysfunction. Ann Intern Med 2007;147:251-62.
5. Arribas F, Auricchio A,Wolpert C, Merkely B, Merino JL, Boriani G et al. The EHRA White Book. Europace 2012;14(Suppl 3):iii1-55.
6. CammAJ, Nisam S. European utilization of the implantable defibrillator: has 10 years changed the 'enigma' Europace 2010;12:1063-9.
7. Disertori M, El-Sherif N. Primary prevention of sudden cardiac death.Doweneed to implant a defibrillator in all the patients with low ejection fraction. Ital Heart J 2004;5: 643-7.
8. Buxton AE, Lee KL, Hafley GE, Pires LA, Fisher JD, GoldMRet al. Limitations of ejection fraction for prediction of sudden death risk in patients with coronary artery disease. Lessons from MUSTT study. J Am Coll Cardiol 2007;50:1150-7.
9. Tung R, Zimetbaum P, Josephson ME. A critical appraisal of implantable cardioverter-defibrillator therapy for the prevention of sudden cardiac death. J Am Coll Cardiol 2008;52:1111-21.
10. Brignole M. Are complications of implantable defibrillators under-estimated and benefits over-estimated Europace 2009;11:1129-33.
11. Katritsis DG, Josephson ME. Sudden cardiac death and implantable cardioverterdefibrillators: two modern epidemics Europace 2012;14:787-94.
12. Epstein AE, DiMarco JP, Ellenbogen KA, Estes NAM, Freedman RA, Gettes LS et al. 2012 ACCF/AHA/HRS focused update incorporated into the ACCF/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society, developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. Circulation 2013;127:e283-352.
13. Epstein AE, DiMarco JP, Ellenbogen KA, EstesNA3rd, Freedman RA, Gettes LS et al. ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities. Areport of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing committee to revise the ACC/AHA/NASPE 2002 guidelines update for implantation of cardiac pacemakers and antiarrhythmia devices) developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. J Am Coll Cardiol 2008;51: e1-62.
14. Russo AM, StainbackRF, Bailey SR, Epstein AE, Heidenreich PA, JessupMet al.ACCF/HRS/AHA/ASE/HFSA/SCAI/SCCT/SCMR 2013 appropriate use criteria for implantable cardioverter-defibrillators and cardiac resynchronization therapy: a report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, Heart Rhythm Society, American Heart Association, American Society of Echocardiography, Heart Failure Society of America, Society of Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, and Society for Cardiovascular Magnetic Resonance. J Am Coll Cardiol 2013;61: 1318-68.
15. Huikuri HV, Castellanos A, Myerburg RJ. Sudden death due to cardiac arrhythmias. N Engl J Med 2001;345:1473-82.
16. Stecker EC, Vickers C,Waltz J, Socoteanu C, John BT, Mariani R et al. Populationbased analysis of sudden cardiac death with and without left ventricular systolic dysfunction: two-year findings from the Oregon Sudden Unexpected Death Study. J Am Coll Cardiol 2006;47:1161-6.
17. Fishman GI, Chugh SS, DiMarco JP, Albert CM, Anderson ME, Bonow RO et al. Sudden cardiac death prediction and prevention: report from a National Heart, Lung, and Blood Institute and Heart Rhythm Society Workshop. Circulation 2010; 122:2335-48.
18. Gupta A, Hoang DD, Karliner L, Tice JA, Heidenreich P, Wang PJ et al. Ability of microvolt T-wave alternans to modify risk assessment of ventricular tachyarrhythmic events: a meta-analysis. Am Heart J 2012;163:354-64.
19. Merchant FM, Ikeda T, Pedretti RF, Salerno-Uriarte JA, Chow T, Chan PS et al. Clinical utility of microvolt T-wave alternans testing in identifying patients at high or low risk of sudden cardiac death. Heart Rhythm 2012;9:1256-64.
20. Calò L, De Santo T, Nuccio F, Sciarra L, De Luca L, Stefano LM et al. Predictive value of microvolt T-wave alternans for cardiac death or ventricular tachyarrhythmic events in ischemic and nonischemic cardiomyopathy patients: a meta-analysis. Ann Noninvasive Electrocardiol 2011;16:388-402.
21. Klem I,WeinsaftJW, Bahnson TD, Hegland D, KimHW, Hayes B et al. Assessment of myocardial scarring improves risk stratification in patients evaluated for cardiac defibrillator implantation. J Am Coll Cardiol 2012;60:408-20.
22. Wu KC, Gerstenblith G, Guallar E, Marine JE, Dalal D, Cheng A et al. Combined cardiac magnetic resonance imaging and C-reactive protein levels identify a cohort at low risk for defibrillation firings and death. Circ Cardiovasc Imaging 2012; 5:178-86.
23. Gao P, Yee R, Gula L, Krahn AD, Skanes A, Leong-Sit P et al. Prediction of arrhythmic events in ischemic and dilated cardiomyopathy patients referred for implantable cardiac defibrillator. Evaluation of multiple scar quantification measures for late gadolinium enhancement magnetic resonance imaging. Circ Cardiovasc Imaging 2012;5:448-56.
24. Fernandez-Armenta J, Berruezo A, Mont L, Sitges M, Andreu D, Silva E et al. Use of myocardial scar characterization to predict ventricular arrhythmia in cardiac resynchronization therapy. Europace 2012;14:1578-86.
25. Leyva F, Taylor RJ, FoleyPW,UmarF, Mulligan LJ, PatelKet al. Left ventricular midwall fibrosis as a predictor of mortality and morbidity after cardiac resynchronization therapy in patients with nonischemic cardiomyopathy. J Am Coll Cardiol 2012;60: 1659-67.
26. Muller KA, Muller I, Kramer U, Kandolf R, Gawaz M, BauerAet al. Prognostic value of contrast-enhanced cardiac magnetic resonance imaging in patients with newly diagnosed non-ischemic cardiomyopathy: cohort study. PLoS ONE 2013;8:e57077.
27. Gulati A, Jabbour A, Ismail TF, Guha K, Khwaja J, Raza S et al. Association of fibrosis with mortality and sudden cardiac death in patients with nonischemic dilated cardiomyopathy. JAMA 2013;309:896-908.
28. Scott PA, Rosengarten JA, Curzen NP, Morgan JM. Late gadolinium enhancement cardiac magnetic resonance imaging for the prediction of ventricular tachyarrhythmic events: a meta-analysis. Eur J Heart Fail 2013; Apr 4: .
29. Elliot P, Andersson B, Arbustini E, Bilinska Z, Cecchi F, Charron P et al. Classification of the cardiomyopathies: a position statement from the European Society of Cardiology working group on myocardial and pericardial diseases. Eur Heart J 2008;29: 270-6.
30. Kron J, SauerW, Schuller J, Bogun F, Crawford T, SarsamS et al. Efficacy and safety of implantable cardiac defibrillators for treatment of ventricular arrhythmias in patients with cardiac sarcoidosis. Europace 2013;15:347-54.
31. Heck PM, Roberts PR. The role of implantable cardiac defibrillators in cardiac sarcoidosis: saviour or sinner Europace 2013;15:309-10.
32. van Rijsingen IA, Arbustini E, Elliott PM, Mogensen J, Hermans-van Ast JF, van der Kooi AJ et al. Risk factors for malignant ventricular arrhythmias in lamin A/C mutation carriers. A European cohort study. J Am Coll Cardiol 2012;59:493-500.
33. Diegoli M, Grasso M, Favalli V, Serio A, Gambarin FI, Klersy C et al. Diagnostic work-up and risk stratification in X-linked dilated cardiomyopathies caused by dystrophin defects. J Am Coll Cardiol 2011;58:925-34.
34. Betts TR, Sadarmin PP, Tomlinson DR, Rajappan K,Wong KCK, de Bono JP et al. Absolute risk reduction in total mortality with implantable cardioverter defibrillators: analysis of primary and secondary prevention trial data to aid risk/benefit analysis. Europace 2013;15:813-19.
35. Zecchin M, Merlo M, Pivetta A, Barbati G, Lutman C, Gregori D et al. How can optimization of medical treatment avoid unnecessary implantable cardioverterdefibrillator implantations in patients with idiopathic dilated cardiomyopathy presenting with 'SCD-HeFT' criteria Am J Cardiol 2012;109:729-35.
36. TeeterWA, Thibodeau JT, Rao K, Brickner ME, Toto KH, Nelson LL et al. The natural history of new-onset heart failure with a severely depressed left ventricular ejection fraction: implications for timing of implantable cardioverter-defibrillator implantation. Am Heart J 2012;164:358-64.
37. Sheppard R, Mather PJ, Alexis JD, Starling RC, Boehmer JP, Thohan V et al. Implantable cardiac defibrillators and sudden death in recent onset nonischemic cardiomyopathy: results from IMAC2. J Card Fail 2012;18:675-81.
38. Bansch D, Antz M, Boczor S, Volkmer M, Tebbenjohanns J, Seidl K et al. Primary prevention of sudden cardiac death in idiopathic dilated cardiomyopathy: the Cardiomyopathy Trial (CAT). Circulation 2002;105:1453-8.
39. Strickberger SA, Hummel JD, Bartlett TG, Frumin HI, Schuger CD, Beau SL et al. Amiodarone versus implantable cardioverter-defibrillator: randomized trial in patients with nonischemic dilated cardiomyopathy and asymptomatic nonsustained ventricular tachycardia-AMIOVIRT. J Am Coll Cardiol 2003;41:1707-12.
40. Kadish A, Dyer A, Daubert JP, Quigg R, Estes NA, Anderson KP et al. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med 2004;350:2151-8.
41. Desai AS, Fang JC, Maisel WH, Baughman KL. Implantable defibrillators for the prevention of mortality in patients with nonischemic cardiomyopathy. A meta-analysis of randomized controlled trials. JAMA 2004;292:2874-9.
42. Theuns DA, Smith T, Hunink MG, Bardy GH, Jordaens L. Effectiveness of prophylactic implantation of cardioverter-defibrillators without cardiac resynchronization therapy in patients with ischaemic or non-ischaemic heart disease: a systematic review and meta-analysis. Europace 2010;12:1564-70.
43. Golberger JJ, Cain ME, Hohnloser SH, Kadish AH, Knight BP, Lauer MS et al. American Heart Association/American College of Cardiology/Heart Rhythm Society scientific statement on noninvasive risk stratification techniques for identifying patients at risk for sudden cardiac death. A scientific statement from the American Heart Association Council on clinical cardiology committee on electrocardiography and arrhythmias and Council on epidemiology and prevention. J Am Coll Cardiol 2008; 52:1179-99.
44. Gorgels AP, Gijsberg C, de Vreed-Swagemakers J, Lousberg A, Wellens HJ. Out-of-hospital cardiac arrest-the relevance of heart failure. The Maastricht Circulatory Arrest Registry. Eur Heart J 2003;24:1204-9.
45. Adabag S, Roukoz H, Anand IS, Moss AJ. Cardiac resynchronization therapy in patients with minimal heart failure: a systematic review and meta-analysis. J Am Coll Cardiol 2011;58:935-41.
46. Poole JE, Gleva MJ, Mela T, Chung MK, Uslan DZ, Borge R et al.; for the REPLACE Registry Investigators. Complication rates associated with pacemakeror implantable cardioverter-defibrillator generator replacements and upgrade procedures. Results from the REPLACE Registry. Circulation 2010;122:1553-61.
47. Poole JE, JohnsonGW, Hellkamp AS, Anderson J, Callans DJ, RaittMHet al. Prognostic importance of defibrillator shocks in patients with heart failure.NEngl J Med 2008; 359:1009-17.
48. Germano JJ, Reynolds M, Essebag V, Josephson ME. Frequency and causes of implantable cardioverter-defibrillator therapies: is device therapy proarrhythmic Am J Cardiol 2006;97:1255-61.
49. Packer DL, Prutkin JM, Hellkamp AS, Mitchell LB, Bernstein RC,Wood F et al. Impact of implantable cardioverter-defibrillator, amiodarone, and placebo on the mode of death in stable patients with heart failure: analysis from the Sudden Cardiac Death in Heart Failure Trial. Circulation 2009;120:2170-6.
50. Hershberger RE, Siegfried JD. Update 2011: clinical and genetic issues in familial dilated cardiomyopathy. J Am Coll Cardiol 2011;57:1641-9.
51. Pasotti M, Klersy C, Pilotto A, Marziliano N, Rapezzi C, Serio A et al. Long-term outcome and risk stratification in dilated cardiolaminopathies. J Am Coll Cardiol 2008;52:1250-60.
52. Quarta G, Syrris P, Ashworth M, Jenkins S, Zuborne Alapi K, Morgan J et al. Mutation in the Lamin A/C gene mimic arrhythmogenic right ventricular cardiomyopathy. Eur Heart J 2012;33:1128-36.
53. Garcia-Pavia P, Syrris P, Salas C, Evans A, Mirelis JG, Cobo-Marcos M et al. Desmosomal protein gene mutations in patients with idiopathic dilated cardiomyopathy undergoing cardiac transplantation: a clinicopathological study. Heart 2011;97: 1744-52.
54. Hershberger RE, Lindenfeld J, Mestroni L, Seidman CE, Taylor MR, Towbin JA et al. Genetic evaluation of cardiomyopathy-A Heart Failure Society of America practice guideline. J Card Fail 2009;15:83-97.
55. Das MK, MaskounW, Shen C, Michael MA, Suradi H, DesaiMet al. Fragmented QRS on twelve-lead electrocardiogram predicts arrhythmic events in patients with ischemic and nonischemic cardiomyopathy. Heart Rhythm 2010;7:74-80.
56. Cheema A, Khalid A, Wimmer A, Bartone C, Chow T, Spertus JA et al. Fragmented QRSand mortality risk in patients with left ventricular dysfunction. Circ Arrhythm Electrophysiol 2010;3:339-44.
57. GrimmW, Hoffmann J, Menz V, Luck K, Maisch B. Programmed ventricular stimulation for arrhythmia risk prediction in patients with idiopathic dilated cardiomyopathy and nonsustained ventricular tachycardia. J Am Coll Cardiol 1998;32:739-45.
58. Kramer DB, Friedman PA, Kallinen LM, Morrison TB, Crusan DJ, Hodge DO et al. Development and validation of a risk score to predict early mortality in recipients of implantable cardioverter-defibrillators. Heart Rhythm 2012;9:42-6.
59. Levy WC, Lee KL, Hellkamp AS, Poole JE, Mozaffarian D, LinkerDTet al. Maximizing survival benefit with primary prevention implantable cardioverter-defibrillator therapy in a heart failure population. Circulation 2009;120:835-42.
60. Cutler MJ, Rosenbaum DS. Risk stratification for sudden cardiac death: is there a clinical role for T wave alternans Heart Rhythm 2009;6:S56-61.
61. Costantini O, Hohnloser SH, KirkMM, Lerman BB, Baker JH 2nd, Sethuraman B et al. The ABCD (Alternans Before Cardioverter Defibrillator) trial. Strategies using T-wave alternans to improve efficiency of sudden cardiac death prevention. J Am Coll Cardiol 2009;53:471-9.
62. Hohnloser SH, Ikeda T, Cohen RJ. Evidence regarding clinical use of microvolt T-wave alternans. Heart Rhythm 2009;6:S36-44.
63. Selvaraj RJ, Picton P, Nanthakumar K, Mak S, Chauhan VS. Endocardial and epicardial repolarization alternans in human cardiomyopathy: evidence for spatiotemporal heterogeneity and correlation with body surface T-wave alternans. J Am Coll Cardiol 2007;49:338-46.
64. Verrier RL, Klingenheben T, Malik M, El-Sherif N, Exner DV, Hohnloser SH et al. Microvolt T-wave alternans. Physiological basis, methods of measurement, and clinical utility-Consensus Guideline by International Society for Holter and Noninvasive Electrocardiology. J Am Coll Cardiol 2011;58:1309-24.
65. Kitamura H, Ohnishi Y, Okajima K, Ishida A, Galeano E, Adachi K et al. Onset heart rate of microvolt-level T-wave alternans provides clinical and prognostic value in nonischemic dilated cardiomyopathy. J Am Coll Cardiol 2002;39:295-300.
66. GrimmW, Christ M, Bach J, Muller HH, Maisch B. Noninvasive arrhythmia risk stratification in idiopathic dilated cardiomyopathy: results of the Marburg Cardiomyopathy Study. Circulation 2003;108:2883-91.
67. Hohnloser Sh, Klingenheben T, Bloomfield D, Dabbous O, Cohen RJ. Usefulness of microvolt T-wave alternans for prediction of ventricular tachyarrhythmic events in patients with dilated cardiomyopathy: results from a prospective observational study. J Am Coll Cardiol 2003;41:2220-4.
68. Bloomfield DM, Bigger JT, Steinman RC, Namerow PB, Parides MK, Curtis AB et al. Microvolt T-wave alternans and risk of death or sustained ventricular arrhythmias in patients with left ventricular dysfunction. J Am Coll Cardiol 2006;47:456-63.
69. Salerno-Uriarte JA, De Ferrari GM, Klersy C, Pedretti RF, Tritto M, Sallusti L et al. Prognostic value of T-wave alternans in patients with heart failure due to nonischemic cardiomyopathy. Results of the ALPHA Study. J Am Coll Cardiol 2007; 50:1896-904.
70. Gold MR, Ip JH, Costantini O, Poole JE, McNulty S, Mark DB et al. Role of microvolt T-wave alternans in assessment of arrhythmia vulnerability among patients with heart failure and systolic dysfunction: primary results from the T-wave alternans SuddenCardiac Death in Heart Failure Trial substudy. Circulation 2008;118:2022-8.
71. Shizuta S, Ando K, Nobuyoshi M, Ikeda T, Yoshino H, Hiramatsu S et al. Prognostic utility of T-wave alternans in a real-world population of patients with left ventricular dysfunction: the PREVENT-SCD study. Clin Res Cardiol 2012;101:89-99.
72. Gehi AK, Stein RH, Metz LD, Gomes JA. Microvolt T-wave alternans for risk stratification of ventricular tachyarrhythmic events.Ameta-analysis. JAmColl Cardiol 2005; 46:75-82.
73. De Ferrari GM, Sanzo A. T-wave alternans in risk stratification of patients with nonischemic dilated cardiomyopathy: can it help to better select candidates for ICD implantation Heart Rhythm 2009;6:S29-35.
74. van derAvoort CJ, Filion KB,Dendukuri N, Brophy JM. Microvolt T-wave alternans as a predictor of mortality and severe arrhythmias in patients with left ventricular dysfunction: a systematic review and meta-analysis. BMC Cardiovasc Disord 2009;9:5.
75. Chan PS, Gold MR, Nallamothu BK. Do beta-blockers impact microvolt T-wave alternans testing in patients at risk for ventricular arrhythmias A meta-analysis. J Cardiovasc Electrophysiol 2010;21:1009-14.
76. Richardson PJ. Assessment of myocardial damage in dilated cardiomyopathy. Eur Heart J 1996;17:489-90.
77. Wu TJ, Ong JJ, Hwang C, Lee JJ, Fishbein MC, Czer L et al. Characteristics of wave fronts during ventricular fibrillation in human hearts with dilated cardiomyopathy: role of increased fibrosis in the generation of reentry. J Am Coll Cardiol 1998;32: 187-96.
78. Soejima K, StevensonWG,Sapp JL, Selwyn AP, Couper G, EpsteinLMet al. Endocardial and epicardial radiofrequency ablation of ventricular tachycardia associated with dilated cardiomyopathy. The importance of low-voltage scars. J AmColl Cardiol 2004; 43:1834-42.
79. Bogun FM, Desjardins B, Good E, Gupta S, Crawford T, Oral H et al. Delayed-enhanced magnetic resonance imaging in nonischemic cardiomyopathy. Utility for identifying the ventricular arrhythmia substrate. J Am Coll Cardiol 2009; 53:1138-45.
80. Kanoupakis EM, Manios EG, Kallergis EM, Mavrakis HE, Goudis CA, Saloustros IG et al. Serum markers of collagen turnover predict future shocks in implantable cardioverter-defibrillator recipients with dilated cardiomyopathy on optimal treatment. J Am Coll Cardiol 2010;55:2753-9.
81. Flevari P, Theodorakis G, Leftheriotis D, Kroupis C, Kolokathis F, Dima Ket al. Serum markers of deranged myocardial collagen turnover: their relation to malignant ventricular arrhythmias in cardioverter-defibrillator recipients with heart failure. Am Heart J 2012;164:530-7.
82. Moon JC, Reed E, Sheppard MN, Elkington AG, Ho SY, BurkeMet al. The histologic basis of late gadolinium enhancement cardiovascular magnetic resonance in hypertrophic cardiomyopathy. J Am Coll Cardiol 2004;43:2260-4.
83. Assomull RG, Prasad SK, Lyne J, Smith G, Burman ED, Khan M et al. Cardiovascular magnetic resonance, fibrosis, and prognosis in dilated cardiomyopathy. J Am Coll Cardiol 2006;48:1977-85.
84. Iles L, Pfluger H, Lefkovits L, Butler MJ, Kistler PM, KayeDMet al. Myocardial fibrosis predicts appropriate device therapy in patients with implantable cardioverterdefibrillators for primary prevention of sudden cardiac death. J Am Coll Cardiol 2011;57:821-8.
85. Lehrke S, Lossnitzer D, Schob M, Steen H, Merten C, Kemmling H et al. Use of cardiovascular magnetic resonance for risk stratification in chronic heart failure: prognostic value of late gadolinium enhancement in patients with non-ischaemic dilated cardiomyopathy. Heart 2011;97:727-32.
86. Seegers J, Vos MA, Flevari P, Willems R, Sohns C, VollmannDet al. Rationale, objectives, and design of the EUTrigTreat Clinical Study: a prospective observational study for arrhythmia risk stratification and assessment of interrelationships among repolarization markers and genotype. Europace 2012;14:416-22.